{
    "clinical_study": {
        "@rank": "63819", 
        "arm_group": [
            {
                "arm_group_label": "End stage renal disease", 
                "arm_group_type": "Experimental", 
                "description": "8 subjects with end stage renal disease on hemodialysis"
            }, 
            {
                "arm_group_label": "Matched healthy subjects", 
                "arm_group_type": "Active Comparator", 
                "description": "8 healthy subjects matched with subjects from Group 1 by sex, age, weight, and smoking status"
            }, 
            {
                "arm_group_label": "Less severe renal impairment", 
                "arm_group_type": "Experimental", 
                "description": "8 subjects with less severe renal impairment"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effect of kidney disease on the absorption,\n      distribution, metabolism, and elimination of a single dose of alisporivir. The safety and\n      tolerability of administering a single dose of alisporivir to patients with end stage renal\n      disease will also be evaluated. Kidney disease is not expected to have a significant effect\n      on the absorption, distribution, metabolism, elimination, safety, or tolerability of\n      alisporivir."
        }, 
        "brief_title": "Evaluate the Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Diasease on Hemodialysis Compared to Healthy Subjects.", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Kidney Failure, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Failure, Chronic", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects on a stable hemodialysis regimen (defined as a Kt/V urea above 1.2 within\n             the past 4 weeks without significant change in the past three months) (only required\n             for subjects with end stage renal disease only)\n\n          -  Subjects in good health as determined by past medical history, physical examination,\n             vital signs, laboratory tests, and other assessments (only required for matched\n             healthy subjects)\n\n        Exclusion Criteria:\n\n          -  Use of another experimental drug within 30 days before enrollment\n\n          -  A positive Hepatitis B or Hepatitis C test result\n\n          -  History of drug or alcohol abuse within 12 months prior to dosing\n\n          -  History of weakened immunity or a positive human immunodeficiency virus (HIV) test\n             result\n\n          -  History or evidence of any inherited bilirubin disease or disorder, including but no\n             necessarily limited to Dubin-Johnson Syndrome, Gilbert's syndrome, and Rotor Syndrome"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975337", 
            "org_study_id": "CDEB025A2112"
        }, 
        "intervention": [
            {
                "arm_group_label": "End stage renal disease", 
                "description": "Single oral dose of alisporivir 400 mg administered within 2 hours after dialysis", 
                "intervention_name": "DEB025", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Matched healthy subjects", 
                    "Less severe renal impairment"
                ], 
                "description": "Single oral dose of alisporivir 400 mg", 
                "intervention_name": "DEB025", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Orlando", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32809"
                }, 
                "name": "Novartis Investigative Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label Study to Evaluate the Pharmacokinetics and Safety of a Single Oral Dose of Alisporivir (DEB025) in Subjects With End Stage Renal Disease on Hemodialysis Compared to Matched Healthy Subjects", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Plasma concentration of alisporivir", 
            "safety_issue": "No", 
            "time_frame": "Pre-dose (0 hours) and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, and 65 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975337"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Blood pressure and pulse rate", 
                "safety_issue": "Yes", 
                "time_frame": "Pre-dose: Screening, Baseline, 0 hours; Post-dose: 4 hours, 6 hours, 8 hours, 1 day, 2 days, 3 days, and 14 days"
            }, 
            {
                "measure": "Hematology and blood chemistry", 
                "safety_issue": "Yes", 
                "time_frame": "Pre-dose: Screening and Baseline; Post-dose: 1 day, 3 days, and 14 days"
            }, 
            {
                "measure": "Urinalysis (healthy subjects only)", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, Baseline, and 14 days post-dose"
            }, 
            {
                "measure": "Adverse event review", 
                "safety_issue": "Yes", 
                "time_frame": "Screening through 14 days post-dose"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}